Janusita Plus Tablet 50/1000 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
MFDS item code 201503222 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used as an adjunctive therapy to assist patients with type 2 diabetes in controlling their blood sugar levels, when combined with dietary and exercise therapy. The combination of sitagliptin and metformin works together to effectively improve blood glucose levels. Therefore, it strengthens blood sugar management and provides positive effects on diabetes treatment.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy in whom adequate glycemic control cannot be achieved with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily; the dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and existing dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, and is used for diabetes treatment. Firstly, serious allergic reactions may occur during the use of this medication, so if skin rash, hives, difficulty breathing, or swelling of the face or neck occurs, you must stop taking the medication immediately and consult a healthcare professional. Additionally, acute pancreatitis, which is inflammation of the pancreas, can rarely occur, so if severe abdominal pain, nausea, or vomiting occurs, you should visit the hospital immediately. The metformin in this medication may cause lactic acidosis, a rare but serious metabolic disorder, so symptoms such as sudden muscle pain, difficulty breathing, fatigue, or abdominal pain must be reported immediately to a healthcare professional. Patients with poor kidney function, dehydration, severe infections, or heart failure should not take this medication, and it must be temporarily discontinued before surgery or examinations using iodinated contrast agents. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. Regular monitoring of kidney function and blood tests are required during the use of this medication, as vitamin B12 deficiency may occur, and vitamin supplementation may be necessary if needed. There is also a risk of hypoglycemia, so meals should be taken regularly, and caution should be exercised regarding hypoglycemic symptoms when combined with other hypoglycemic agents. Excessive alcohol consumption or vigorous exercise may increase the risk of side effects from this medication, so it is advisable to avoid them. Finally, if bullous skin disorders or severe joint pain occur during medication use, consult a doctor immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container that is well-ventilated, and it is advisable to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication and prevent degradation.
Red oval film-coated tablet
30 tablets (10 tablets/PTP*3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jeil Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.